The current U.S. reference-product labeling identifies several tofacitinib dosage forms.
| Dosage form | Labeled strength |
|---|---|
| Immediate-release XELJANZ tablet | 5 mg |
| Immediate-release XELJANZ tablet | 10 mg |
| XELJANZ XR extended-release tablet | 11 mg |
| XELJANZ XR extended-release tablet | 22 mg |
| XELJANZ oral solution | 1 mg/mL |
The website identifies Tofacent 5 mg as a tofacitinib product. The specific Tofacent dosage form, appearance, excipients and packaging require verification.
Why strengths matter
Different strengths and formulations are not interchangeable simply because they contain the same active ingredient. For example, the current U.S. label specifically states that XELJANZ XR is not substitutable with XELJANZ tablets or oral solution without appropriate professional direction.
5 mg strength
A 5 mg immediate-release tofacitinib tablet is an established reference-product strength. The 5 mg regimen is used in several adult maintenance settings under U.S. labeling, but the appropriate regimen depends on the condition and patient factors.
Product-specific verification
Whether Tofacent is supplied as a tablet, its precise formulation and whether it is authorized in a particular jurisdiction are Incepta Pharmaceuticals Ltd.